Celgene Corporation (CELG) Completes Acquisition of Avila Therapeutics
3/8/2012 6:47:19 AM
More...
|
Celgene (CELG) Acquisition of The Leukemia & Lymphoma Society Partner, Avila Therapeutics, Significant Advance for Novel Blood Cancer Therapy
1/27/2012 10:59:41 AM
More...
|
Celgene (CELG) to Acquire Avila Therapeutics for Up to $925 Million
1/26/2012 7:10:22 AM
More...
|
Avila Therapeutics Announces FDA Allowance of Partner Clovis Oncology (CLVS)’s IND Application for CO-1686, an Oral EGFR Mutant-Selective Inhibitor, Triggers $4 Million Milestone Payment to Avila
1/20/2012 7:17:05 AM
More...
|
Avila Therapeutics to Present at J.P. Morgan Healthcare Conference
1/3/2012 6:56:45 AM
More...
|
Avila Therapeutics Presents Data on AVL-292, a Selective Bruton’s Tyrosine Kinase Inhibitor, for the Treatment of B Cell Cancers at the 2011 American Society of Hematology Annual Meeting
12/12/2011 11:10:23 AM
More...
|
Avila Therapeutics to Present at the 2011American Society of Hematology Annual Meeting
12/5/2011 6:28:14 AM
More...
|
Avila Therapeutics Presents Clinical and Preclinical Data on AVL-292 Showing Potential for the Treatment of Autoimmune Disease at the 2011 American College of Rheumatology Annual Scientific Meeting
11/8/2011 7:21:05 AM
More...
|
Avila Therapeutics to Present at Lazard Capital Markets 8th Annual Healthcare Conference
11/7/2011 4:21:42 PM
More...
|
Avila Therapeutics Completes Dosing of First Patient Cohort in Phase 1b Clinical Study of AVL-292, a Selective Bruton's Tyrosine Kinase Inhibitor for the Treatment of B Cell Cancers
9/14/2011 9:04:09 AM
More...
|
|